Friday, February 4, 2022

Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines - PubMed

https://pubmed.ncbi.nlm.nih.gov/22495656/

Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage - PubMed

https://pubmed.ncbi.nlm.nih.gov/28847725/

Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway - PMC

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8650430/

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes - PMC

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7272521/

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug - PubMed

https://pubmed.ncbi.nlm.nih.gov/32474842/

Ivermectin as an inhibitor of cancer stem‑like cells - PubMed

https://pubmed.ncbi.nlm.nih.gov/29257278/

Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth - PubMed

https://pubmed.ncbi.nlm.nih.gov/34483925/

Ivermectin, a potential anticancer drug derived from an antiparasitic drug - PMC

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7505114/

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug - PMC

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5835698/